Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx”
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
👨⚕️ Matin Imanguli, JHU Sidney Kimmel Comprehensive Cancer Center LAO📍 3 sites📅 Started Aug 2026View details ↗
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
👨⚕️ Lin Shen, Peking University Cancer Hospital & Institute📍 7 sites📅 Started Feb 2026View details ↗
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
👨⚕️ yuecan zeng, doctor, The Second Affiliated Hospital of Hainan Medical University📍 1 site📅 Started Feb 2026View details ↗
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
👨⚕️ Jiang D Sui, Ph.D, M.D., Chongqing University Cancer Hospital📍 1 site📅 Started Feb 2026View details ↗
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
RecruitingNCT07376603 ↗
IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
👨⚕️ Xiaolong Yan, The Second Affiliated Hospital of Air Force Medical University📍 1 site📅 Started Dec 2025View details ↗
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
RecruitingNCT07232680 ↗
Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
👨⚕️ Rodney Cheng En Hsieh, MD, PhD, Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2025View details ↗
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
👨⚕️ Zhihao MM Lu, PHD, Peking University Cancer Hospital & Institute📍 1 site📅 Started Nov 2025View details ↗
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Page 1 of 9Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →